A single dose of the lysergide orally disintegrating tablet achieved statistically significant MADRS improvement at six weeks compared …
A single dose of the lysergide orally disintegrating tablet achieved statistically significant MADRS improvement at six weeks compared …
Amtagvi becomes the first tumour-infiltrating lymphocyte therapy approved in Australia for advanced melanoma, entering a market with the …
June’s pharmaceutical headlines reflect significant regulatory shifts, industry reorganization, and technological innovation shaping healthcare policy and drug development.
Landmark ASCO results and advances in liquid biopsy-driven treatment switching spotlight innovation in cancer research and personalized medicine.
Novavax’s protein-based COVID-19 vaccine, Nuvaxovid, wins FDA approval for older adults and people with underlying health risks under …
FDA greenlights two major therapies offering new hope for patients with IgA nephropathy and giant cell arteritis
On 15 April 2025, the European Medicines Regulatory Network rolled out an interactive trial map—empowering patients and professionals …
A landmark study from MHRA and University of Liverpool reveals the UK’s leadership in drug development and outlines …
Prime Minister Starmer unveils ambitious reforms to speed up trial timelines and centralize NHS data, aiming to restore …
An investigational RNA-based therapy shows significant reduction in disease-causing protein levels—potentially a meaningful step forward in treating Huntington’s …
Already a subscriber? Log in